SinoMab BioScienceのIPO年
SinoMab BioScienceのIPO年は何ですか。
SinoMab BioScience LimitedのIPO年は2019です。
IPO年の定義は何ですか。
新規公開株 (IPO)は、企業の株式を通常は機関投資家に販売し、順番に証券取引所で一般市民に販売する株式公開の一種です。
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
HKSEのセクタHealth CareにおけるIPO年の企業と比べるSinoMab BioScience
SinoMab BioScienceは何をしますか。
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
SinoMab BioScienceと類似のipo年
- W.I.S.E. - Nasdaq Overseas China New Economy Companies Top 50 Index Tracker FundのIPO年は2018です。
- iShares II Public - iShares $ TIPS UCITS ETFのIPO年は2018です。
- Ladenburg Thalmann Services 7.00% SN NT 28のIPO年は2018です。
- CSOP Hong Kong Dollar Money Market ETFのIPO年は2018です。
- Tempus ResourcesのIPO年は2018です。
- China Asset Management company Bloomberg Barclays China Treasury Policy Bank bond index ETFのIPO年は2018です。
- SinoMab BioScienceのIPO年は2019です。
- Del Taco RestaurantsのIPO年は2020です。
- CenteneのIPO年は2020です。
- Novo Nordisk A/SのIPO年は2020です。
- Pensana Rare Earths PlcのIPO年は2020です。
- Auralite InvestmentsのIPO年は2020です。
- TilrayのIPO年は2020です。